Photodynamic therapy of the surface form of basalioma and actinic keratosis with the topical administration of methyl aminolevulinate

Cover Page


Cite item

Full Text

Abstract

Goal. To assess the efficacy of the photodynamic therapy with the external use of methyl aminolevulinate as a photosensitizer with further irradiation with visible red light with the wavelength of 630 nm in the treatment of patients suffering from a surface form of basalioma and actinic keratosis. Materials and methods. The study involved 28 patients diagnosed with the surface form of basalioma and 34 patients diagnosed with actinic keratosis. They underwent treatment by the photodynamic therapy method using a LED lamp radiating visible red light with the wavelength of 630 nm, with the total dose of irradiation equal to 37 J/cm2. All patients also underwent a confocal in vivo laser scanning microscopy of lesions at the baseline and after 7, 30, 90 and 180 days of treatment. Results. Absolute regression of abnormal lesions was observed in 25 (91%) patients diagnosed with the surface form of basalioma and 30 (88.9%) patients diagnosed with actinic keratosis after 30 days of treatment. No signs of the diseases were revealed in these patients after examination by the method of confocal in vivo laser scanning microscopy. Conclusion. The photodynamic therapy with the local administration of methyl aminolevulinate with further irradiation with visible red light with the wavelength of 630 nm is an efficient method of treatment of the surface form of basalioma and actinic keratosis.

About the authors

A. A. Kubanova

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

A. A. Kubanov

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: noemail@neicon.ru
Russian Federation

I. N. Kondrakhina

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: noemail@neicon.ru
Russian Federation

N. V. Gribanov

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: gribanov@cnikvi.ru
Russian Federation

References

  1. Kaprin A.D., Starinskij V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2013 godu (Zabolevaemost' i smertnost'). M: MNIOI im. P.A. Gercena filial FGBU «FMIC im. P.A. Gercena» Minzdrava Rossii. 2015.
  2. Suhova T.E., Molochkov V.A., Romanko YU.S. i soavt. Lechenie bazal'nokletochnogo raka kozhi na sovermennom ehtape. Al'manah klinicheskoj mediciny. 2008; 18: 14-21.
  3. Gistologicheskaya klassifikaciya opuholej kozhi. VOZ. Zheneva, 1996. [Гистологическая классификация опухолей кожи. ВОЗ. Женева, 1996.]
  4. Scales S.J., de Sauvage F.J. Mechanisms of Hedgehog pathway activation in cancer implications for therapy. Trends Pharmacol Sci. 2009; 30 (6): 303-312.
  5. Ozgur O.K., Yin V., Chou E. et al. Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol. 2015; Epub ahead of print. 112^ № 4, 2015
  6. Abidi A. Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas. Indian J Pharmacol. 2014; 46: 3-12.
  7. Otsuka A., Levesque M.P., Dummer R., Kabashima K. Hedgehog signaling in basal cell carcinoma. J Dermatol Sci. 2015; 78 (2): 95-100.
  8. Sobin L.H., Gospodarovich M., Vittekind K. TNM Klassifikaciya zlokachestvennyh opuholej. М.: Logosfera, 2011, 288 s.
  9. Dubenskij V.V., Dubenskij Vl.V. Novoobrazovaniya kozhi v praktike dermatovenerologa. Voprosy ehpidemiologii, ehtiopatogeneza i diagnostiki. Vestn dermatol venerol 2008; 6: 22-40.
  10. Volgin V.N., Sokolova T.V., Kolbina M.S., Sokolovskaya A.A. Bazal'no-kletochnyj rak kozhi: ehpidemiologiya, patogenez, klinicheskaya kartina (chast' 1). Vestn dermatol venerol 2013; 2: 6-14.
  11. Volgin V.N., Sokolova T.V., Kolbina M.S., Sokolovskaya A.A. Bazal'no-kletochnyj rak kozhi: diagnostika, lechenie (chast' 2). Vestn dermatol venerol 2013; 2: 16-23
  12. Volgin V.N., Sokolova T.V. Osobennosti techeniya bazal'no-kletochnogo raka kozhi v sovremennyh usloviyah. Vrach. 2009; 2: 6-9.
  13. Yantsos V.A., Conrad N., Zabawski E., Cockerell C.J. Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Semin Cutan Med Surg 1999; 18 (1): 13-14.
  14. Schwartz R.A., Bridges T.M., Butani A.K., Ehrlich A. Actinic keratosis: an occupational and environmental disorder. J Eur Acad Dermatol Venereol 2008; 22 (5): 606-615.
  15. Glogau R.G. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42 (1): 23-24.
  16. Ko C.J. Actinic keratosis: facts and controversies. Clin Dermatol 2010; 28 (3): 249-253.
  17. Rossi R., Mori M., Lotti T. Actinic keratosis. Int J Dermatol 2007; 46 (9): 895-904.
  18. Criscione V.D., Weinstock M.A., Naylor M.F. et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial Cancer 2009; 115 (11): 2523-2530.
  19. Lever L.R., Farr P.M. Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. Br J Dermatol 1994; 131 (2): 215-219.
  20. Nindl I., Gottschling M., Krawtchenko N. et al. Low prevalence of p53, p16(INK4a) and Haras tumour-specific mutations in low-graded actinic keratosis. Br J Dermatol 2007; 156, 3: 34-39.
  21. Jorizzo J.L., Carney P.S., Ko W.T. et al. Treatment options in the management of actinic keratosis. Cutis 2004; 74 (6): 9-17.
  22. Stockfleth E., Ferrandiz C., Grob J.J. et al. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18 (6): 651-659.
  23. Cyb A.F., Kaplan M.A., Romanko Yu.S., Popuchiev V.V. Fotodinamicheskaya terapiya. M: Medicinskoe informacionnoe agentstvo, 2009.
  24. Stranadko E.F. Istoricheskij ocherk razvitiya fotodinamicheskoj terapii. Lazernaya medicina. 2002; (1): 4-8.
  25. Szeimies R.M., Karrer S., Radakovic-Fijan S. et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. J Am Acad Dermatol 2002; 47 (2): 258-62.
  26. Morton C., Campbell S., Gupta G. et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006; 155 (5): 1029-1036.
  27. Mclntyre W.J., Downs M.R., Bedwell S.A. Treatment options for actinic keratoses. Am Fam Physician 2007; 76 (5): 667-671.
  28. Weinberg J.M. Topical therapy for actinic keratosis: current and evolving therapies. Rev Recent Clin Trials 2006; 1 (1): 53-60.
  29. Moan J., Ma L.W., Iani V. On the pharmacokinetics of topically applied 5-aminolevulinic acid and two of its esters. Int J Cancer 2001; 92 (1): 139-143.
  30. Casas A., Fukuda H., Di Venosa G., Batlle A. Photosensitization and mechanism of cytotoxicity induced by the use of ALA derivatives in photodynamic therapy. Br J Cancer 2001; 85 (2): 279-284.
  31. Butov Yu.S., Vasenova V.Yu., Ivanova M.S. et al. Actinic keratosis clinical-morphological characteristics and its healing with photodynamic therapy application. Vestn estet med 2012; 1: 36-42.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2015 Kubanova A.A., Kubanov A.A., Kondrakhina I.N., Gribanov N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies